Sawgrass Asset Management LLC Buys Shares of 27,337 United Therapeutics Corporation $UTHR

Sawgrass Asset Management LLC purchased a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 27,337 shares of the biotechnology company’s stock, valued at approximately $11,460,000. United Therapeutics makes up approximately 1.4% of Sawgrass Asset Management LLC’s holdings, making the stock its 17th biggest holding. Sawgrass Asset Management LLC owned approximately 0.06% of United Therapeutics at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. F m Investments LLC lifted its stake in United Therapeutics by 1.3% in the second quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company’s stock worth $741,000 after acquiring an additional 33 shares during the period. HB Wealth Management LLC raised its holdings in shares of United Therapeutics by 2.9% in the 2nd quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company’s stock valued at $355,000 after purchasing an additional 35 shares in the last quarter. WealthCollab LLC lifted its position in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares during the period. Park Avenue Securities LLC boosted its stake in shares of United Therapeutics by 1.7% during the second quarter. Park Avenue Securities LLC now owns 2,353 shares of the biotechnology company’s stock valued at $676,000 after purchasing an additional 39 shares in the last quarter. Finally, Coldstream Capital Management Inc. increased its holdings in United Therapeutics by 2.0% during the second quarter. Coldstream Capital Management Inc. now owns 2,145 shares of the biotechnology company’s stock valued at $616,000 after buying an additional 43 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Price Performance

Shares of UTHR stock opened at $468.94 on Friday. The stock’s fifty day moving average price is $487.66 and its 200 day moving average price is $414.96. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $519.99. The company has a market cap of $20.19 billion, a price-to-earnings ratio of 17.77, a price-to-earnings-growth ratio of 2.51 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping the consensus estimate of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The business had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. During the same quarter last year, the company earned $6.39 earnings per share. The company’s quarterly revenue was up 6.8% on a year-over-year basis. As a group, equities research analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Jefferies Financial Group restated a “buy” rating and set a $575.00 target price on shares of United Therapeutics in a report on Wednesday, November 19th. Royal Bank Of Canada boosted their price target on United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research report on Thursday, October 30th. UBS Group raised their price objective on United Therapeutics from $600.00 to $645.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Morgan Stanley set a $447.00 target price on shares of United Therapeutics in a report on Wednesday, October 29th. Finally, Wells Fargo & Company increased their price target on shares of United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research report on Thursday, October 30th. Eight investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $509.50.

Insider Activity at United Therapeutics

In other United Therapeutics news, Director Jan Malcolm sold 50 shares of the company’s stock in a transaction that occurred on Tuesday, December 23rd. The shares were sold at an average price of $512.12, for a total transaction of $25,606.00. Following the transaction, the director owned 420 shares in the company, valued at approximately $215,090.40. This represents a 10.64% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $469.89, for a total transaction of $3,900,087.00. Following the sale, the executive vice president owned 36,781 shares of the company’s stock, valued at $17,283,024.09. The trade was a 18.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 563,364 shares of company stock worth $266,247,272 in the last quarter. 10.30% of the stock is currently owned by company insiders.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.